Comparative Pharmacology
Head-to-head clinical analysis: APRISO versus BALSALAZIDE DISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRISO versus BALSALAZIDE DISODIUM.
APRISO vs BALSALAZIDE DISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) that acts locally in the colon to reduce inflammation by inhibiting prostaglandin and leukotriene synthesis, scavenging free radicals, and activating peroxisome proliferator-activated receptor-gamma (PPAR-γ).
Prodrug that delivers mesalamine (5-aminosalicylic acid) to the colon; mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene synthesis, and scavenges reactive oxygen species, thereby decreasing colonic inflammation.
1.5 g (3 capsules) orally once daily in the morning. Each capsule contains 0.5 g mesalamine.
2.25 g (three 750 mg capsules) orally three times daily
None Documented
None Documented
8.6 ± 4.2 hours for mesalamine; after multiple dosing, effective half-life ~12 hours. Clinical context: allows twice-daily dosing.
Balsalazide itself has a terminal elimination half-life of approximately 0.5–1 hour; the active moiety mesalamine has a terminal half-life of 5–10 hours, which may be prolonged in renal impairment.
Renal (primarily as acetylated metabolite, ~80%) and fecal (~20%).
Primarily excreted in feces via biliary elimination (approximately 90%) following conversion to mesalamine; renal excretion accounts for less than 10% of the dose as mesalamine and its metabolites.
Category C
Category C
Aminosalicylate
Aminosalicylate